# Study of the PD-L1 Inhibitor Atezolizumab With or Without Low-dose, Local Radiation in Patients With Relapsed or Refractory Advanced Stage Follicular Lymphoma

> **NCT03465891** · PHASE2 · TERMINATED · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 2 (actual)

## Conditions studied

- Lymphoma

## Interventions

- **DRUG:** atezolizumab
- **RADIATION:** Low- Dose, Local Radiotherapy

## Key facts

- **NCT ID:** NCT03465891
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-03-09
- **Primary completion:** 2019-12-17
- **Final completion:** 2019-12-17
- **Target enrollment:** 2 (ACTUAL)
- **Why stopped:** Low accrual and lack of funding.
- **Last updated:** 2021-01-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03465891

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03465891, "Study of the PD-L1 Inhibitor Atezolizumab With or Without Low-dose, Local Radiation in Patients With Relapsed or Refractory Advanced Stage Follicular Lymphoma". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03465891. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*